Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Synchrony Financial (SYF) Price & Performance

BioNano Genomics IncTrade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Synchrony Financial — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Synchrony Financial trades at $74.21 (market cap $24.78B). The key difference: Synchrony Financial is far larger — about 1877.3× BioNano Genomics Inc's market cap, and Synchrony Financial pays a 1.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOSYF
Market Cap
$13.20M$24.78B
Sector
HealthFinancials
52-Week High
$4.92$88.47
52-Week Low
$1.09$63.78
Enterprise Value
$15.81M
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Synchrony Financial

SYF trades at $73.21, up 1.06% today, with a bearish technical signal but strong fundamentals. The stock shows a low P/E of 7.63 and robust profitability with a 24.06% net income margin. Recent earnings beats and a $0.30 dividend highlight operational strength, while analyst consensus is bullish with a $86.38 price target.

Outlook remains positive due to earnings momentum and undervaluation, but risks include economic sensitivity and technical weakness. The stock offers value with upside potential, though investors should monitor loan performance and interest rate impacts on financial results.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF